Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in Granulomatosis with Polyangiitis: results from a single centre.
Objective: Rituximab (RTX) is an anti-CD20 antibody used successfully in Granulomatosis with Polyangiitis (GPA) for induction and maintenance of remission. Our study aims to evaluate the long term efficacy and safety of chronic pre-emptive RTX therapy in GPA.
PublisherUiT Norges arktiske universitet
UiT The Arctic University of Norway
CitationEUVAS Conference, 13.04.2013
The following license file are associated with this item: